The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach